Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel
NASDAQ:SLDB

Solid Biosciences Q4 2025 Earnings Report

Solid Biosciences logo
$7.20 +0.30 (+4.35%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$7.20 +0.00 (+0.07%)
As of 07:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Solid Biosciences EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Solid Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Solid Biosciences Announcement Details

Quarter
Q4 2025
Date
3/19/2026
Time
Before Market Opens
Conference Call Date
Thursday, March 19, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Solid Biosciences' Q1 2026 earnings is estimated for Friday, May 8, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, May 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Solid Biosciences' Q4 2025 Press ReleasePress Release
(8-K)
Solid Biosciences' Q4 2025 Annual reportAnnual report
(10-K)

Solid Biosciences Earnings Headlines

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/01/3286204/0/en/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284790/0/en/solid-biosciences-to-showcase-a-large-presence-at-the-29th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy.html
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
May 7 at 1:00 AM  |  Brownstone Research (Ad)
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
April 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/solid-biosciences-announces-receipt-of-european-commission-orphan-drug-designation-for-sgt-003-for-the-treatment-of-duchenne-muscular-dystrophy-1036071552
Analysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB)
April 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SYK/pressreleases/1340330/analysts-are-bullish-on-these-healthcare-stocks-stryker-syk-solid-biosciences-sldb/
Solid Biosciences Adjusts Board Classes in Governance Move
April 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SLDB-Q/pressreleases/1259626/solid-biosciences-adjusts-board-classes-in-governance-move/
See More Solid Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email.

About Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector. In addition to SGT‐001, the company is advancing next-generation programs including SGT-003, a CRISPR/Cas9‐based gene editing approach aimed at correcting specific dystrophin gene mutations, and proprietary assays for sensitive detection of dystrophin expression in muscle tissue.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Solid Biosciences leverages partnerships with academic institutions and patient advocacy groups to support clinical development and expand its understanding of DMD biology. Its clinical studies have been conducted at sites across the United States and Europe, reflecting the global nature of DMD research and the need for broad patient enrollment in rare-disease trials.

Under the leadership of Chief Executive Officer Ilan Ganot, Solid Biosciences maintains a network of research and manufacturing collaborations to enhance vector production and assay development. The company’s mission remains to deliver transformative therapies to DMD patients by advancing innovative genetic medicines and building the infrastructure required for efficient clinical translation.

View Solid Biosciences Profile
Earnings Tools